[PRNewswire] More People Treated With Once-weekly Semaglutide Achieved
Reductions in Both Glucose and Weight vs. Comparator Treatments
-- Poster # 820
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(LISBON, Portugal, September 12, 2017 PRNewswire=연합뉴스) A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). The analysis was presented today at the 53rd Annual Meeting of the European Association For The Study Of Diabetes.[1]
"As a physician, helping patients with type 2 diabetes achieve glycaemic and weight loss targets can be challenging," said Dr Helena Rodbard, SUSTAIN 5 investigator and medical director at Endocrine and Metabolic Consultants, Rockville, Maryland. "The meaningful reductions demonstrated with semaglutide in both glucose and body weight are encouraging, as more treatment strategies are needed to help meet this challenge."
Significantly more people treated with once-weekly semaglutide achieved the clinically meaningful composite endpoint of ≥1% HbA1c reduction and ≥5% weight loss with 0.5 mg (25-35%) and 1.0 mg (38-56%) semaglutide vs. all comparators (2-13%; p<0.0001) in SUSTAIN 1-5.[1]<br>
In addition, more people achieved the composite endpoint with once-weekly semaglutide 1.0 mg compared with semaglutide 0.5 mg (p<0.0001 for SUSTAIN 2, 4 and 5; p=0.17 for SUSTAIN 1).[1]<br>
In this post-hoc analysis, semaglutide was well tolerated, with a safety profile similar to that of other glucagon-like peptide-1 receptor agonists. The most common adverse event with semaglutide was nausea. In SUSTAIN 1-4, severe or blood glucose confirmed symptomatic hypoglycaemia events were fewer or similar with once-weekly semaglutide vs. comparators. In SUSTAIN 5, on a background of basal insulin, more events were observed with once-weekly semaglutide than with placebo.[1]
About semaglutide
Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake.[2]-[5] Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
About the SUSTAIN clinical trial programme
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3a global clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook [http://www.facebook.com/novonordisk ], Twitter [http://www.twitter.com/novonordisk ], LinkedIn [http://www.linkedin.com/company/novo-nordisk ], YouTube [http://www.youtube.com/novonordisk ]
Novo Nordisk A/S
Corporate Affairs
Novo Alle
2880 Bagsværd
Denmark
Telephone: +45-4444-8888
Internet: http://www.novonordisk.com
CVR no: 24 25 67 90
References
1. Rodbard H, Bellary S, Hramiak I, et al. Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.
2. Korsatko A, Brunner M, Sach-Friedl S, et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.
3. Kapitza C, Dahl K, Jaconsen B, et al. The effects of once-weekly semaglutide on ß-cell function in subjects with type 2 diabetes. Abstract 754. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.
4. Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; ePub ahead of print. DOI: 10.1111/dom.12932.
5. Saad H, Hjersted J, Axelsen MB, et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes. 2016; 40:S34-S35.
Further information
Media:
Katrine Sperling
+45-4442-6718
krsp@novonordisk.com
Asa Josefsson
+45-3079-7708
aajf@novonordisk.com
Investors:
Peter Hugreffe Ankersen
+45-3075-9085
phak@novonordisk.com
Hanna Ogren
+45-3079-8519
haoe@novonordisk.com
Anders Mikkelsen
+45-3079-4461
armk@novonordisk.com
Christina Jensen
+45-3079-3009
cnje@novonordisk.com
Kasper Veje (US)
+1-609-235-8567
kpvj@novonordisk.com
Source: Novo Nordisk
(끝)
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>